donor-derived ebv-specific cytotoxic t-cells transduced with the retroviral vector sfgalpha-cd19-cd3zeta
Cell therapyexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT01195480)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human herpesvirus 4Immunity, passive
Human herpesvirus 4 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- donor-derived ebv-specific cytotoxic t-cells transduced with the retroviral vector sfgalpha-cd19-cd3zeta
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01195480 | Phase 1/Phase 2 (Phase 2) | May 1, 2012 | Department of Health, United Kingdom, Deutsche Krebshilfe e.V., European Union, JP Moulton Charitable Foundation, The Leukemia and Lymphoma Society, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Health, United Kingdom | Government | 1 | 0 | 1 | 2012 |
| Deutsche Krebshilfe e.V. | Academic/Hospital | 1 | 0 | 1 | 2012 |
| European Union | Government | 1 | 0 | 1 | 2012 |
| JP Moulton Charitable Foundation | Academic/Hospital | 1 | 0 | 1 | 2012 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2012 |
6 organizations
Page 1 / 1